Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.


             
 

Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.

Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.

Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.

Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.

Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.



NAVIGATION


         

 

A study published in a special issue of Photochemistry and Photobiology examines the emerging practice of drug delivery systems which use the application of light to activate medications in the body. The process uses biocompatible materials that are sensitive to certain physiological variables or external physicochemical stimuli. Changes in external or internal body conditions can be used to achieve control of the delivery.

 

Fluidigm Corporation announced a sample quantification system that allows researchers to sequence their libraries of rare samples and also dramatically lower costs, improve data quality and speed up time-to-results for scientists performing next-generation DNA sequencing. Fluidigm’s new product, called SlingShot™, improves the productivity of next generation sequencing tools from Roche, Illumina and Applied Biosystems.

 

Background Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead. We investigated the hypothesis …

 

Sorin Group (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, and Orange Business Services, the leading global communications solutions integrator, announced an agreement to develop and service a remote monitoring solution for patients implanted with cardiac rhythm management (CRM) devices.

 

A recent Montana State University master’s graduate is working with doctors at Vanderbilt Medical Center in Tennessee to build a handheld laser microscope that could someday reduce the number of biopsies needed to diagnose skin cancer. Suspicious spots on the skin often prompt dermatologists to remove skin samples for analysis.

 

W. L. Gore & Associates (Gore) announced that it has received approval from the US Food and Drug Administration (FDA) to market a 31 mm diameter version of the GORE EXCLUDER® AAA Endoprosthesis. The device provides physicians with a safe and effective endovascular option to treat abdominal aortic aneurysms (AAA) in patients with aortic inner neck diameters up to 29 mm.

 

A new study released by the national consumer rights group Center for Justice & Democracy finds that medical devices for the heart have caused thousands of needless injuries and deaths, yet patients currently have no legal recourse against reckless medical device manufacturers.

 

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for individuals with age-related macular degeneration (AMD), announced the FDA Ophthalmic Devices Advisory Panel unanimously recommended that the FDA approve, with conditions, the premarket application (PMA) for its implantable telescope for End-Stage AMD.

 

Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced that it will begin marketing and distributing the new C. DIFF QUIK CHEK COMPLETE(TM) rapid test as an in vitro diagnostic aid for Clostridium difficile associated disease (CDAD). This follows TECHLAB(R), Inc.

 

Removing thrombus from coronary arteries with the Export Aspiration Catheter from Medtronic, Inc. (NYSE:MDT), before implanting a stent in patients suffering a specific kind of heart attack, “results in excellent clinical outcomes,” at one year, according to new data released today at the American College of Cardiology (ACC) meeting.




March 2009
Mon Tue Wed Thu Fri Sat Sun
« Feb   Apr »
 1
2345678
9101112131415
16171819202122
23242526272829
3031